SLDB - NASDAQ

Solid Biosciences Inc.

SLDB·NASDAQ

$6.85

+4.1%

HealthcareBiotechnology

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$533.68M

EPS-1.9900

P/E Ratio-3.44

Earnings Date08/11/2026

232.54M

Assets

23%

3Y-11.0%

5Y+36.0%

10Y+472.0%

52.53M

Total Liabilities

3Y+8.0%

5Y+34.0%

10Y-33.0%

180.01M

Total Equity

31%

3Y-15.0%

5Y+36.0%

10Y-575.0%

Solid Biosciences Inc. Funding & Solvency Profile

SLDB · NASDAQ

Current Assets

Cash & Cash Equivalents59.90M

Net Receivables0.00

Inventory0.00

Other Current Assets17.61M

Total Current Assets205 M

Non-Current Assets

Property, Plant & Equipment26.09M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets991.00K

Total Non-Current Assets27 M

Total Assets

232.54M

Financial Health Analysis

Current Ratio

6.14x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.29x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

172 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

88% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Solid Biosciences Inc. Balance Sheet

SLDB • NASDAQ

Solid Biosciences Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	59.9M	80.2M	74M	155.4M	119.1M	154.7M	76M	86.4M	52.1M	7.7M	28.6M
Short-Term Investments	128M	68.7M	49.6M	58.3M	88.6M	0.0	7.5M	36.1M	17M	30M	26.8M
Cash & Short-Term Investments	187.9M	148.9M	123.6M	213.7M	207.8M	154.7M	83.5M	122.5M	69.1M	37.7M	55.4M
Net Receivables	0.0	0.0	0.0	0.0	110K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	110K	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	6.7M	4M	2.9M	6M	2.7M	1.3M	4.4M	951K	2.1M	221K
Other Current Assets	17.6M	1.7M	2.1M	3M	8.7M	1.5M	1.5M	1.8M	613K	235K	88K
Total Current Assets	205.5M	157.3M	129.7M	219.6M	222.6M	158.9M	86.3M	128.6M	70.7M	40M	55.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	26.1M	29M	33.2M	38.6M	7.6M	11.7M	16.6M	10.4M	2.4M	452K	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	327K	0.0	0.0	0.0	0.0
Other Non-Current Assets	991K	2.3M	2M	2M	2.2M	536K	209K	536K	3.1M	212K	0.0
Total Non-Current Assets	27.1M	31.4M	35.2M	40.6M	9.8M	12.3M	17.2M	11M	5.5M	664K	0.0
Total Assets	232.5M	188.7M	164.9M	260.3M	232.4M	171.2M	103.5M	139.6M	76.2M	40.6M	55.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.2M	4.2M	2M	3.2M	4.5M	3.3M	7.1M	3.7M	5.1M	3M	608K
Accounts Payable	3.2M	4.2M	2M	3.2M	4.5M	3.3M	7.1M	3.7M	5.1M	3M	608K
Accrued Expenses	0.0	13.6M	4.2M	8.3M	6.4M	4.8M	3.6M	3.5M	2M	1.2M	260K
Short Term Debt	2.1M	0.0	0.0	0.0	0.0	0.0	1.9M	173K	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3M	2.3M	2.6M	1.5M	2.2M	1.9M	173K	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	8.1M	10.4M	9.2M	8.2M	233K	345K	0.0
Other Current Liabilities	28.1M	9.4M	5.9M	8.4M	3.1M	3.8M	-5.5M	4.9M	4.2M	2.4M	13.1M
Total Current Liabilities	33.5M	30.3M	14.5M	22.5M	23.6M	24.5M	18.3M	12.5M	11.3M	6.9M	13.9M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	5.1M	859K	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	10.4M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	96K	0.0	1.3M	-5.1M	215K	0.0	71.6M	61.7M
Total Non-Current Liabilities	19.1M	21.2M	23.9M	26.1M	568K	14.6M	5.1M	1.9M	124.2M	71.6M	61.7M
Capital Lease Obligations	19.1M	24.2M	26.3M	28.5M	2.1M	5.2M	7.1M	1M	0.0	0.0	0.0
Total Liabilities	52.5M	51.4M	38.5M	48.6M	24.2M	39.1M	23.4M	14.4M	135.5M	78.5M	75.6M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-558K	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	139.6M	124.2M	71.6M	61.7M
Common Stock	79K	40K	20K	20K	7K	87K	48K	35K	65M	558K	208K
Additional Paid-In Capital	1.1B	920.6M	785.2M	774.5M	685M	536.6M	396.3M	324.2M	65M	558K	0.0
Retained Earnings	-957.8M	-783.5M	-658.8M	-562.7M	-476.8M	-404.6M	-316.3M	-199.1M	-124.3M	-84.9M	-67.7M
Accumulated Other Comprehensive Income/Loss	52K	47K	15K	-68K	-45K	0.0	1K	-5K	-13K	23K	-10K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-65M	-72.2M	-61.7M
Total Stockholders' Equity	180M	137.2M	126.5M	211.7M	208.2M	132.1M	80M	125.2M	-59.3M	-84.4M	-67.5M
Total Equity	180M	137.2M	126.5M	211.7M	208.2M	132.1M	80M	125.2M	-59.3M	-37.9M	-19.9M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.5M	47.6M
SUMMARY
Total Liabilities & Equity	232.5M	188.7M	164.9M	260.3M	232.4M	171.2M	103.5M	139.6M	76.2M	40.6M	55.7M
Total Investments	128M	68.7M	49.6M	58.3M	88.6M	0.0	7.5M	36.1M	17M	30M	26.8M
Total Debt	21.2M	24.2M	26.3M	28.5M	2.1M	5.2M	7.1M	1M	0.0	0.0	0.0
Net Debt	-38.7M	-56.1M	-47.8M	-126.8M	-117.1M	-149.6M	-69M	-85.3M	-52.1M	-7.7M	-28.6M
Shares Outstanding	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071	77,869,071

SEC Filings

SLDB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 10, 2026	April 10, 2026	2026	View Filing
S-3 S-3 N/A	March 19, 2026	March 19, 2026		View Filing
S-3 S-3 N/A	March 19, 2026	March 19, 2026		View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 03, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 127 filings

Related Guides

Blog Categories

Continue your SLDB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.